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Gastric Cancer - An Overview
K M ChU,* FRCS(Ed). FACS. FHKAM(Surgery), FCSHK
Department of Surgery
Queen Mary Hospital
Summary
Gastric cancer remains the second leading cause of cancer-related deaths worldwide. Apart from dietary factors,
Helicobacter pylori is currently considered as one of the most important risk factors. The incidence of gastric cancer
in Hong Kong is not high enough to justify population screening with upper endoscopy. Clinical features, however,
can be quite non-specific. Patients may be asymptomatic, especially during early stage of the disease. Upper
endoscopy should be considered in patients presenting with recent onset of ulcer-like symptoms, weight loss, symptoms
of obstruction, bleeding or anaemia, especially if they are elderly. By the time clinical features of metastases are
apparent, the disease would be beyond cure. In recent years, endoscopic ultrasonography and staging laparoscopy
have greatly enhanced the pre-operative staging accuracy. Such information will be important if neoadjuvant
chemotherapy is contemplated for advanced disease. At present, surgery remains the mainstay of potentially curative
treatment. Post-operative adjuvant chemotherapy is not recommended unless on a proper trial basis. Early results
of pre-operative neoadjuvant chemotherapy are encouraging but further studies are required to confirm its efficacy.
For unresectable gastric cancer, various treatment options are available and selection has to be individualised. (HK
Pract 1999;21:357-364)
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Introduction
Despite a steady decline in
i n c i d e n c e in many deve loped
countries, gastric cancer continues to
be the second leading cause of
cancer-related deaths worldwide.1 In
Hong Kong, it is the fourth leading
cause of cancer-related deaths.2
Complete surgical extirpation of the
tumour remains the mains tay of
potentially curative treatment. If
discovered early, prior to dissemina-
tion of disease, gastric cancer is
curable after surgical resection.
Nevertheless, despite advances in
medical knowledge and technology,
gastric cancer is rarely diagnosed at
an early stage. In Japan, where the
incidence of gastric cancer is high
and screening is practised, early
* Address for correspondence: Dr. K M Chu, Associate Professor, Division of Upper Gastrointestinal Surgery, Department of Surgery, University of Hong
Kong Medical Centre, Queen Mary Hospital, Pokfulam Road, Hong Kong.
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gastric cancer confined to the mucosa
or submucosa constitutes about 50%
of all new cases. 3 In Western
countries as well as in Hong Kong,
however, approximately two thirds of
patients with gastric cancer present
with stage III or IV disease.4 Curative
s u r g i c a l r e sec t ion i s t h e r e f o r e
impossible in the majority of patients.
The prognosis of the disease remains
dismal because of the d e l a y in
presen ta t ion as w e l l as a h i g h
recurrence rate despite an apparent
cu ra t i ve resect ion for advanced
disease.
Epidemiology
Gastric cancer has a predilection
f o r m a l e s i n v i r t u a l l y e v e r y
population studied. Geographically,
there is wide variation in incidence of
gastric cancer in different parts of the
world. Japan has one of the highest
incidence in the world; the incidence
rate in Japan is about 8.5 times that
observed in North America. Other
areas with high incidence include, for
example, China, Costa Rica, Korea,
Chile, Poland, and the former Soviet
Union. Various epidemiological
studies have examined a number of
potential risk factors which might
help explain the global variation in
incidence. In general, gastric cancer
appears to have a m u l t i f a c t o r i a l
aetiology, and the etiological factors
m a y h a v e d i f f e r e n t r e l a t i v e
importance in different parts of the
world. Traditionally, dietary factors
have been g i v e n the g r e a t e s t
emphasis, although there is no single
dietary item that could account for all
the differences in cancer incidence.
Gastric cancer has previously been
reported to be associated with an
increased dietary intake of N-nitroso
compounds, nitrites and salts, and a
decreased intake of ascorbate, fresh
f r u i t s and vegetables . 1 A l l i u m
vegetables, like onion and garlic, may
play a protective role by detoxifying
carcinogens.5 Other risk factors for
gastric cancer include smoking, a
past history of partial gastrectomy,
f a m i l y h i s t o r y o f the d isease ,
p e r n i c i o u s a n a e m i a , a t r o p h i c
gastri t is , Menetrier's disease, and
adenomatous polyps of the stomach.
Nowadays, Helicobacter pylori
has been considered as one of the
most important risk factors for gastric
cancer. The International Agency for
Research on Cancer (IARC) of the
World Hea l th Organ i s a t i on has
recently classified H. pylori as a
Group I carcinogen, a definite cause
of g a s t r i c a d e n o c a r c i n o m a in
humans. 6 More evidence has been
accumulated to support its role in
gastric carcinogenesis.7 It is not yet
certain whether global eradication of
the bacteria wi l l help in bringing
down the incidence of the disease. A
vaccine for the prevention of chronic
H. pylori i n f e c t i o n is not yet
available for clinical use. Screening
for and eradication of H. pylori in
asymptomatic individuals is currently
not recommended.
Pathology
Macroscopically, gastric cancer
could be divided into four types
accord ing to the Borrmann's
c lass i f i ca t ion (1926): polypoid ,
fungating, ulcerative, and infiltrative.
Linitis plastica represents a special
type of g a s t r i c cancer which
infiltrates diffusely below the gastric
mucosa . Endoscop ica l ly , the
stomach with l in i t i s plastica appears
rigid but there is no macroscopic
mucosal lesion.
His to log ica l ly , the Lauren's
classification (1965) separates gastric
cancer into intestinal and diffuse
types. These two types of carcinoma
differ from each other with respect to
their epidemiology, pathogenesis, and
behaviour. In general, the intestinal
type of carcinoma is more distally
located and is associated with a better
prognosis in comparison wi th the
diffuse type.
Gastric cancer disseminates by
four main routes. Locally, gastric
cancer may infil trate directly into
surrounding structures like pancreas,
transverse colon, mesocolon or liver.
Lymphatic spread to the regional
l y m p h nodes i s common and
s u p r a c l a v i c u l a r l y m p h n o d e
metastasis signifies systemic spread.
Liver is one of the common organs
involved by haematogenous spread.
When a gastric cancer penetrates the
serosa, cancer cells may exfoliate
into the peritoneal cavity resulting in
p e r i t o n e a l d i s s e m i n a t i o n , o r
transcoelomic spread. Apart from
peritoneal seedlings and ascites, the
o v a r y m a y b e i n v o l v e d b y
transcoelomic spread (also called
Krukenberg tumour).
The staging of gastric cancer is
according to the TNM evaluation. T
stands for the penetration of the
gastric wall by the primary tumour.
N stands for the nodal involvement
w h i l e M rep resen t s s y s t e m i c
metastasis. There are three staging
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systems in use. The International
U n i o n A g a i n s t Cancer ( U I C C )
class i f ica t ion is the same as the
American Joint Committee on Cancer
(AJCC) classification.8 The Japanese
Research Society for gastric cancer
(JRSGC) classification differs from
the other two classifications mainly
in the N staging criteria. While the
most recent edition of UICC/AJCC
classification categorises N according
to the absolute n u m b e r of lymph
nodes being positive for metastases,8
the JRSGC classifies lymph nodes
into different stations according to
the i r loca t ion in re la t ion to the
primary tumour.9 The interested
reader may refer to the r e l e v a n t
literatures for further details.
Clinical features
Clinica l features can be quite
n o n - s p e c i f i c . Pa t i en t s may be
asymptomat ic , especia l ly d u r i n g
early stage of the disease. On the
other hand, patients with advanced
disease may p resen t w i t h non-
specific symptoms l ike anorexia,
weight loss, and malaise. Symptoms
such as epigastric pain and distending
discomfort may mimic benign ulcer
disease. In fact, treatment with ulcer
healing drugs either by the patients
themselves or by the unwary medical
practitioner accounts for a significant
proportion of delay in diagnosis.
Otherwise, the presentation of gastric
cancer depends on its locat ion,
w h e t h e r i t has p r o d u c e d any
complication, and whether it has
metastasised. Obstructing tumours in
the gast r ic ou t le t may produce
symptoms like distending discomfort
or vomiting. Tumours in the gastric
inlet (or cardioesophageal junction)
may give rise to dysphagia. Bleeding
from gastric cancer could be overt or
occult. Occult bleeding may lead to
symptoms of anaemia ul t imately .
Acute presentation with symptoms
and signs of upper gastrointestinal
bleeding like coffee ground vomiting
and melaena is not infrequent. Acute
free perforation of gastric cancer,
however , i s u n c o m m o n and the
presentat ion is not different from
perforation of benign peptic ulcer.
Patient with advanced disease may
present wi th an abdomina l mass
w h i c h could be due to a b u l k y
primary tumour, omental secondary,
or ovarian secondary (Krukenberg
tumour). Clinical features of patients
w i t h s y s t e m i c m e t a s t a s e s a r e
d e p e n d e n t on the l o c a t i o n of
metastases (Table 1). Acanthosis
nigricans is an uncommon phenome-
non associated with adenocarcinoma
of the g a s t r o i n t e s t i n a l t r a c t ,
especially gastric cancer. It appears
as hyperpigmented, velvety plaque
that often affects the neck, axilla,
flexor areas, and anogenital region.
The cause of this hyperpigmentation
is currently unknown.
Investigations
Laboratory investigations are
u s u a l l y u n h e l p f u l for diagnosis .
Anaemia may be present as a result
of b l e e d i n g . F l ex ib l e uppe r
endoscopic examination is the most
useful and specific investigation. In
the presence of a gastric ulcer or any
suspicious gastric lesion, mult iple
biopsies should be taken for
h i s to log ic examina t ion even if i t
appears b e n i g n endoscop ica l ly .
Barium meal examination is seldom
required unless endoscopic facility is
not readily available. Serum tumour
markers such as carcinoembryonic
antigen (CEA) and CA 19-9 are non-
specific and cannot be utilised for
diagnostic purposes. On the other
hand, tumour markers may be helpful
Table 1: Clinical features in the presence of metastatic disease
Metastases
Supraclavicular lymph node
Pleura, lung
Peritoneum
Portal lymph node
Liver
Umbilicus
Ovary
Pelvis
Bone
Brain
Clinical features
Enlarged supraclavicular lymph node
Dyspnoea, pleural effusion, haemoptysis
Abdominal distension, ascites, mass, bowel
obstruction
Obstructive jaundice
Hepatomegaly, jaundice (late stage)
Sister Joseph's nodule
Ovarian mass (Krukenberg tumour)
Pelvic nodule, rectal (Blumer's) shelf
Bone pain, pathological fracture
Neurologic deficit, change in conscious state
(Continued on pane 361)
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in patients known to have the disease
wi th raised t i t res for moni tor ing
response to therapy and detection of
recurrence.
After histological confirmation
of gastric carcinoma, the clinician's
task is to determine whe ther the
patient is suitable for surgery. This
will mainly involve the assessment of
the pa t ient ' s f i t n e s s for genera l
anaesthesia as well as screening for
m e t a s t a t i c d isease . C l i n i c a l l y
obvious metastat ic disease should
have been i d e n t i f i e d d u r i n g the
physical examination. A plain chest
x-ray is recommended for screening
metas ta t i c disease as we l l as for
pre-operative assessment. Ultrasono-
graphy or computed tomography
(CT) are of value in the identification
of ascites, liver metastases, or para-
aortic lymphadenopathy. Ultrasono-
g r a p h y , h o w e v e r , i s o p e r a t o r
dependent. Specific investigations
may be a p p l i e d fo r c l i n i c a l l y
suspicious metastatic disease. Fine
needle aspiration for cytology, for
example, wou ld be arranged for
enlarged supraclavicular lymph node.
In recent years, endoscopic
ul t rasonography (EUS) has been
found to be one of the most accurate
methods for assessment of T and N
stages of gastric cancer. Its accuracy
is dependent on the experience of the
endoscopist. At present, usage of
EUS is best limited to specialist
centres where an accurate pre-
operative staging is important as
guidance for inclusion in neoadjuvant
chemotherapy tr ials .1 0 Its use is
probably not warranted in centres
where knowledge of T and N staging
will not affect the surgical decision.
A d v a n c e d g a s t r i c c a n c e r
f r e q u e n t l y spreads t h r o u g h the
peritoneal route. Such peritoneal
seedlings are usua l ly small in size
ini t ia l ly and not visible even on CT
s c a n n i n g . Laparoscopy permits
direct visualisation of the peritoneal
cavity and is the most sensitive and
specific modality for the detection of
peritoneal metastases. The detection
of per i toneal d i s s emina t i on may
obviate the need for laparotomy in
p a t i e n t s who do not require any
pa l l i a t ive surgery for bleeding or
obstruction.
Management
Infrequently, gastric cancer may
perforate acutely with clinical signs
of peritonitis. An emergency gastric
resection may be performed if the
patient 's condition is stable enough
to w i t h s t a n d the procedure . A
s i g n i f i c a n t propor t ion of such
patients can be saved and offered
good p a l l i a t i o n by e m e r g e n c y
gas t r ec tomy. 1 1 In the e l ec t i ve
situation, the management of gastric
cancer depends on the fitness of the
pat ient and the c l in ica l stage of
disease on presentation. At present,
surgery remains the mainstay of
potentially curative treatment. If the
patient is medically unfit for surgery,
only non-surgical options could be
offered.
In Hong Kong, gastric cancer is
rarely diagnosed at an early stage. In
Japan, where screening is practised,
early gastric cancer confined to the
mucosa or submucosa constitutes
about 50% of all new cases. Radical
gastric resection for such patients
carries a five-year survival rate of
about 90% in most series. The
distinctly lower incidence of lymph
node metastasis in early mucosal
cancer, coupled with the morbidity
associated wi th standard radical
gastric resection, has led to the
i n t r o d u c t i o n of o ther forms of
treatment. Such treatment options
can be b r o a d l y c l a s s i f i ed i n t o
endoscopic, laparoscopic and open
surgical techniques. Of the various
endoscopic techniques, endoscopic
mucosal resection (EMR) is probably
the best known. The success of EMR
requires that the lesion is limited to
the mucosa and that there is no lymph
node m e t a s t a s i s . E n d o s c o p i c
ultrasonography is very helpful is this
respect . The genera l se l ec t ion
criteria for EMR include mucosal
l e s i o n , w e l l - d i f f e r e n t i a t e d
adenocarcinoma, lesion of not more
than 2 cm in diameter and absence of
ulceration. For larger lesion or lesion
t h a t i n v a d e s t h e s u b m u c o s a ,
laparoscopic wedge resection or
p a r t i a l gas t rec tomy have been
p e r f o r m e d in v a r i o u s cen t re s .
Modifications to the open surgical
technique include wedge resection,
pylorus-preserving gast rectomy,
vagus-preserving gastrectomy, and
Dl radical gastric resection. Dl
indicates lymph node dissection of
the first tier of lymph node stations
(Nl ) under the Japanese (JRSGC)
classification.
The majority of gastric cancer
diagnosed in Hong Kong, as in other
Western countries, is advanced. The
standard treatment of such patients
involves radical gastric resection
whenever the disease is deemed
resectable. The extent of resection
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depends on the location of tumour.
Dis ta l s u b t o t a l ga s t r ec tomy i s
indicated for a distal lesion whi le
total gastrectomy is indicated for a
lesion in the body or p r o x i m a l
stomach. Splenectomy or distal
pancreatectomy is avoided unless
there is direct tumour involvement.
Splenectomy is associated with a
m a r k e d i n c r e a s e i n s e p t i c
complications. The issue of extended
lymph node dissection has not been
settled. The value of D2 lymph node
dissection, removing the second tier
of lymph node stations (N2) under
the JRSGC classif icat ion, has not
been p r o v e n w i t h t w o r e c e n t
p r o s p e c t i v e r a n d o m i s e d t r i a l s
comparing Dl with D2 dissection.12-13
These s t u d i e s were , h o w e v e r ,
criticised for being multi-centre trials
as well as for their high morbidity
associated wi th distal pancreat-
ectomy. At present, extended lymph
node dissection is best l imi ted to
surgeons wi th experience in the
procedure. Extended lymph node
dissection by inexperienced hands,
albeit out of good will, may do more
harm than good to patients.
The results of surgical resection
vary between different centres.14 In
general, the prognosis worsens with
increasing pathological stages. As a
rough g u i d e l i n e , t he f i v e - y e a r
survival rates after resection for
stages I, II, III, and IV diseases are
about 85%, 50%, 25%, and 10%,
respectively.
The va lue of pos topera t ive
adjuvant chemotherapy has been
questioned. In the hope of reducing
recurrence after surgical resection,
v a r i o u s s t u d i e s o n a d j u v a n t
chemotherapy have been performed
with contradicting results. A meta-
analysis of published randomised
trials on adjuvant chemotherapy after
curative resection for gastric cancer
did not reveal any significant survival
b e n e f i t . 1 5 T h i s s t u d y w a s
subsequently criticised for omitting
one Japanese randomised trial. At
present, adjuvant chemotherapy is not
r e c o m m e n d e d a f t e r s u r g i c a l
resection. Its use should be restricted
to a proper trial setting.
In view of the d i s appo in t ing
results associated with the use of
pos t -opera t ive a d j u v a n t chemo-
therapy and the high recurrence rate
after an apparent curative resection,
pre-operative neoadjuvant chemo-
t h e r a p y h a s been i n t r o d u c e d .
Neoadjuvant chemotherapy may help
reduce locoregional tumour volume
and downstage the disease and thus
increase the chance of complete
tumour resection. Accurate pre-
operative staging, including the use
of endoscopic ultrasonography and
staging laparoscopy, is necessary for
patient selection and proper analysis.
Early results were encouraging but
genuine survival benefit has yet to be
confirmed by proper randomised
trials.
In the presence of systemic
metastases , gast r ic resect ion is
generally not indicated. For patients
with synchronous liver metastases,
palliative gastrectomy did not confer
any prolongation of survival nor
improvement in qual i ty of l i fe .1 6
Palliative surgery may, however, be
indicated in patients with obstruction
or profound bleeding. A palliative
bypass in the form of gastrojejunos-
tomy may be performed for outlet
obs t ruc t ion . A l t e rna t ive ly , for
patients who are unfi t for general
a n a e s t h e s i a , a s e l f - e x p a n d i n g
metal l ic stent could be deployed
endoscopically across the site of
obs t ruc t ion . Pain control is an
i m p o r t a n t f ace t o f p a l l i a t i v e
management and should not be
overlooked. In the presence of a
partially obstructed gastrointestinal
tract, transdermal narcotics would be
an u s e f u l a l t e r n a t i v e to ora l
medication. Neurolytic blockade of
the coe l i ac g a n g l i o n by the
anaesthetist could provide lasting
relief for selected patients having
t u m o u r i n f i l t r a t i o n of the retro-
peritoneum.
Systemic chemotherapy has
been considered to be a possible
treatment option for unresectable
g a s t r i c c a r c i n o m a . Severa l
randomised trials have confirmed
surviva l benefit for unresectable
d i sease t rea ted w i th sys temic
chemotherapy in comparison to best
supportive care alone.17-19 FAMTX (a
m e t h o t r e x a t e - b a s e d r e g i m e n
c o n s i s t i n g of 5 - F l u o r o u r a c i l ,
doxorubicin, and methotrexate) has
been a gold standard in the early 90s.
More recently, ECF (an infusional
5 - F l u o r o u r a c i l - b a s e d r e g i m e n
consisting of epirubicin, cisplatin,
and 5-Fluorouracil) was found to be
a m o r e a c t i v e r e g i m e n t h a n
FAMTX.20 Although the results of
t h e v a r i o u s n e w s y s t e m i c
chemotherapy regimens have been
encouraging, the gain of prolonged
survival is, not infrequently, offset by
systemic toxicity which may lengthen
hospital stay, prolong suffering, and
deprecate the quality of survival.
In the hope of reducing the
systemic toxicity, we have recently
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Figure la: Contrast CT scan abdomen of a patient
with carcinoma of stomach and multiple
bilobar liver metastases (arrows) before
chemotherapy
Figure 1b: Reassessment CT scan of the same patient
revealing significant response of
metastases to regional intra-arterial
therapy. His primary tumour (arrow) also
introduced the use of regional intra-
arterial chemotherapy for unresec-
table gastric carcinoma (Figures la
& 1b). Reg iona l i n t r a - a r t e r i a l
chemotherapy maximises the local
concentration of chemotherapeutic
agents and minimises levels in the
systemic c i r cu l a t i on . The local
effects may thus be enhanced while
systemic side effects are obviated as
far as possible. Our results so far are
encouraging with a clinical response
rate comparable to the best systemic
regimens while the systemic toxicity
is minimal.
Conclusion
The management of gastr ic
cancer has evolved over the years,
With better understanding of its
epidemiology and etiological factors,
preventive measures may hopefully
further reduce its incidence in the
future. The issue of Helicobacter
pylori eradication or vaccination as a
preventive measure is cu r r en t l y
unsettled. Surgery still remains the
most i m p o r t a n t t r e a t m e n t f o r
resectable gastric cancer. It is very
important for the family physician to
be aware of the n o n - s p e c i f i c
presentations of gastric cancer. For
patients with suspicious symptoms,
immediate investigation, preferably
with upper endoscopy, should be
arranged. The only hope for cure is
to diagnose the disease at its early
stages. The role of pre-operative
neoadjuvant chemotherapy will be
further clarified with ongoing studies.
For unresectable disease, various
t rea tment options are available
nowadays. The quality of life of
these patients should not be ignored
when palliative treatment is being
offered. •
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Key messages
1. Helicobacter pylori is considered as one of the most important risk factors for gastric cancer. However,
screening for and eradication of H. pylori in asymptomatic individual is currently not recommended.
2. Patients with suspicious symptoms should be investigated promptly, preferably with upper endoscopy. Do not
wait until the patient develops obvious signs of metastases.
3. Surgery remains the mainstay of potentially curative treatment.
4. Various treatment options are available for unresectable gastric cancer and selection has to be individualised.
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